SCHEMBL7948327

SCHEMBL7948327

COc1c(O)ccc(C=O)c1Cc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
ERN1 O75460 5/20 0.42
TRIM24 O15164 2/20 0.41
TRIM33 Q9UPN9 2/20 0.41
TYR P14679 1/20 0.41
LTA4H P09960 1/20 0.39
PLA2G2A P14555 1/20 0.38
TLR2 O60603 1/20 0.38
TLR1 Q15399 1/20 0.38
TLR6 Q9Y2C9 1/20 0.38
SHBG P04278 1/20 0.38
MCL1 Q07820 2/20 0.38
KDM4E B2RXH2 2/20 0.38
POLB P06746 2/20 0.38
GAA P10253 2/20 0.38
HTT P42858 2/20 0.38
ALDH1A1 P00352 1/20 0.38
IDH1 O75874 1/20 0.38
JAK2 O60674 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL873591 0.85 CA1 (0.40) CA1CA2TYRLTA4HSHBG
SCHEMBL28275335 0.85 CA1 (0.45) CA1CA2KDM4EGAAMAPT
SCHEMBL2875694 0.83 ALDH1A1 (0.50) ERN1LTA4HTLR2TLR1TLR6
SCHEMBL28512054 0.83 PTPN1 (0.41) CA1CA2MAPT
Bicarbonate SCHEMBL28192811 0.82 CA1 (0.38) CA1CA2PLA2G2A
SCHEMBL1396832 0.81 CA1 (0.54) CA1CA2ERN1TRIM24TRIM33
SCHEMBL20455996 0.80 CA1 (0.50) CA1CA2ERN1TRIM24TRIM33
SCHEMBL20506784 0.79 CA1 (0.54) CA1CA2ERN1TRIM24TRIM33
SCHEMBL28909126 0.79 ERN1 (0.46) ERN1TRIM24TRIM33MCL1KDM4E
SCHEMBL7948311 0.79 HNF4A (0.50) HTTALDH1A1MAPTMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015121379-A2 METHODS OF IMPROVING PRODUCTION OF VANILLIN EVOLVA SA (CH) 2015-08-20 WO claimed
CN-107881188-A A kind of method that whole-cell catalyst prepares aromatic aldehyde and/or aromatic alcohol 上海交通大学 2018-04-06 CN disclosed
CN-107266297-A Prenylation hydroxy diphenyl ethylene, the pharmaceutical composition comprising it, purposes and preparation method thereof 悉尼大学 2017-10-20 CN disclosed
US-20160367685-A1 DUPA-INDENOISOQUINOLINE CONJUGATES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-12-22 US disclosed
CN-105899234-A Dupa-indenoisoquinoline conjugates 普度研究基金会 2016-08-24 CN disclosed
WO-2015069766-A1 DUPA-INDENOISOQUINOLINE CONJUGATES PURDUE RESEARCH FOUNDATION (US) 2015-05-14 WO disclosed
US-6261814-B1 MIXING PURIFIED, BIOLOGICALLY-DERIVED REDUCTASE FROM NOCARDIA SPECIES WITH CARBOXYLIC ACID OR DERIVATIVE; PRODUCTION OF VANILLIN FROM VANILLIC ACID UNIVERSITY OF IOWA RESEARCH FOUNDATION 2001-07-17 US disclosed
WO-1998040472-A2 CARBOXYLIC ACID REDUCTASE, AND METHODS OF USING SAME UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 1998-09-17 WO disclosed
US-5795759-A Carboxylic acid reductase, and methods of using same THE UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 1998-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160367685-A1 DUPA-INDENOISOQUINOLINE CONJUGATES PDS5B, KLK3, PDS5A CA1 4807/4885CA2 4742/4885ERN1 4474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.